| Name | Title | Contact Details |
|---|
careMESH is a first-of-its-kind healthcare communications platform bringing together a national provider directory, admit/discharge notifications, secure communications, and transition of care workflows into a single service. careMESH connects the care continuum by allowing any provider working with any electronic health record to communicate and collaborate with any other, instantly. careMESH`s cloud-based services efficiently allow hospitals and health systems, health information exchanges, public health agencies, and physician groups to communicate about patients, maintain complete control over when and where information is shared, and rapidly reduce reliance on outdated tools such as fax and phone calls.
Missoula Orthotics and Prosthetics is a Missoula, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Nox Health is the global sleep health leader committed to helping people wake up to a brighter world. Combining cutting-edge diagnostic capabilities with technology-enabled, full-service treatment solutions, Nox Health helps healthcare payers and providers align to reduce costs, address issues at the individual level and share the life-changing impact of a good night`s sleep. Nox Health is a one-stop, holistic solution helping to identify, address and resolve sleep issues across the globe.
Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company’s products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections. It is also developing SYR-472, which is in Phase III clinical trials for the treatment of Type-2 diabetes. In addition, the company has rights to compounds in various stages of development and commercialization, which includes Nesina, Liovel, Oseni, and Kazano for the treatment of Type-2 diabetes, as well as Priligy for the treatment of premature ejaculation. The company was founded in 1998 and is headquartered in Morrisville, North Carolina.
At the core, GI Alliance operates on a philosophy grounded by three guiding principles: Patient First. Quality Centric. Provider-Led. Our strength comes from the diversity of talented individuals who make up our organization—everyone striving to serve our patients with excellence every day. We have designed our practice to foster and develop a diverse culture, both clinical and non-clinical. It is not merely words for our practice. Our company values and celebrates the diversity of our physicians, staff and patients. We firmly believe our service is greatly enriched by our diversity of thought, experience, perspective, culture and background. The people of GI Alliance are the best in the industry, and that results in a great working environment.